NCT00629876终止1 期
A Phase 1, Multicenter, Open-Label Dose Escalation Study Evaluating the Safety and Tolerability of Multiple Hematide Injections in Subjects With Refractory Non-Small Cell Lung Cancer, Breast Cancer, or Prostate Cancer Who Are Anemic and Receiving Cytotoxic Chemotherapy
Takeda0 个研究点目标入组 2 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 2
- 主要终点
- Maximum tolerated dose.
研究概览
简要总结
The purpose of this study is to determine the safety and tolerability of peginesatide used to treat anemia in subjects diagnosed with recurrent non-small cell lung cancer, breast cancer or prostate cancer and who also receiving a taxane chemotherapy.
详细描述
Currently approved erythropoiesis stimulating agents have been used successfully to increase hemoglobin levels, reduce fatigue and other anemia-related symptoms, improve daily function, and alleviate the need for transfusions of red blood cells in subjects with chronic kidney disease-related anemia or in cancer subjects with chemotherapy-induced anemia.
Peginesatide (hematide) Injection is a parenteral formulation for administration by intravenous or subcutaneous injection that is being developed for the correction of anemia in patients with chronic kidney disease, including patients on dialysis and patients not on dialysis, and for the treatment of patients with anemia due to concomitantly administered chemotherapy.
This is a multicenter, open-label dose escalation study to evaluate the safety, tolerability, and efficacy of multiple doses of peginesatide Injection in subjects with refractory non-small cell lung cancer, breast cancer, or prostate cancer. These subjects must have anemia diagnosed as a result of taxane chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
- •Individuals with one of the following histologically confirmed tumors:
- •stage IIIB/IV non-small-cell lung cancer
- •metastatic breast cancer
- •androgen insensitive prostate cancer and are scheduled to receive at least 4 weeks of chemotherapy, including a taxane.
- •Has progression or relapse after treatment with at least one regimen of chemotherapy or hormone therapy.
- •Has a hemoglobin value of greater than or equal to 8 and less than 10.5 g/dL within 1 week prior to administration of study drug.
- •Has an Eastern Cooperative Oncology Group Performance Status of 0-
- •Has one ferritin level greater than or equal to 100 ng/mL within 4 weeks prior to study drug administration.
- •Has one serum or red cell folate level above the lower limit of normal within 4 weeks prior to study drug administration.
- •Has one vitamin B12 level above the lower limit of normal within 4 weeks prior to study drug administration.
- •Has one absolute neutrophil count greater than or equal to 1.5 x 109/L within 1 week prior to administration of study drug.
- •The subject has a serum creatinine less than or equal to 1.5 mg/dL or a measured creatinine clearance greater than 60 mL/min.
- •The subject has one platelet count greater than or equal to 100 x 109/L within 1 week prior to administration of study drug.
- •The subject has a Life expectancy greater than 4 months.
- •The subject has a body mass index between 18 and 30 kg/m2, inclusive, prior to study drug administration.
- •The subject has a negative test result for hepatitis B surface antigen, and hepatitis C virus antibody at Screening.
排除标准
- •Has a history of failure to respond to erythropoiesis-stimulating agent treatment.
- •Has had treatment with any erythropoiesis-stimulating agent in the past 4 weeks.
- •Is known to have antibodies to other erythropoiesis-stimulating agents or history of Pure Red Cell Aplasia.
- •Has received Peginesatide in a previous clinical study or as a therapeutic agent.
- •Has a history of hypersensitivity or allergies to Peginesatide, other erythropoiesis-stimulating agents or related compounds.
- •Has had red blood cell transfusion within 4 weeks prior to study drug administration.
- •Has known hemoglobinopathy (eg, homozygous sickle-cell disease, thalassemia of all types, etc).
- •Has known hemolytic condition.
- •Has known blood loss as a cause of anemia, iron deficiency anemia, or anemia caused by gastrointestinal bleeding.
- •Has any previous or planned radiotherapy to more than 30% of active bone marrow.
- •Has donated more than 400 mL of blood within the 90 days preceding the beginning of the study.
- •Has known intolerance to parenteral iron supplementation.
- •Has received IV iron within 1 week of study drug administration.
- •Has history of bone marrow or peripheral blood cell transplantation.
- •Has central nervous system metastases.
- •Has a history of deep venous thrombosis, pulmonary embolism or other thrombotic event (eg, stroke, myocardial infarction, etc.) in the previous 6 months or known history of hypercoagulable disorder.
- •Has uncontrolled, or symptomatic inflammatory disease (eg, rheumatoid arthritis, systemic lupus erythematosus, etc).
- •Has poorly controlled hypertension per the investigator's judgment within 4 weeks prior to study drug administration (eg, systolic greater than or equal to 170 mm Hg or diastolic greater than or equal to 100 mm Hg on repeat readings).
- •Has had a seizure in the 6 months prior to study drug administration.
- •Has advanced chronic congestive heart failure - New York Heart Association Class III or IV.
- •Has a history or presence of an abnormal electrocardiogram at Screening that, in the investigator's opinion, is clinically significant.
- •Has a known history of human immunodeficiency virus.
- •Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as consumption of more than 4 alcoholic drinks per day) within 1 year prior to Baseline.
- •Has aspartate aminotransferase or alanine aminotransferase greater than 2.5 times the upper limit of normal (aspartate aminotransferase or alanine aminotransferase greater than 5 times the upper limit of normal if liver metastases are present), active liver disease or jaundice.
- •Is currently taking or anticipated to require anticoagulants other than aspirin (eg, coumadin, ticlopidine, etc.).
- •Has a bilirubin greater than the upper limit of normal.
- •Has pyrexia/fever greater than or equal to 39°C within 48 hours prior to study drug administration.
- •Has high likelihood of early withdrawal or interruption of the study (eg, myocardial infarction within the past 3 months, severe or unstable coronary artery disease, stroke, respiratory, autoimmune, neuropsychiatric or neurological abnormalities, or any other clinically significant medical diseases or conditions within the prior 6 months that may, in the investigator's opinion, interfere with assessment or follow-up of the subject).
- •Has anticipated elective surgery during the study period.
- •Has exposure to any investigational agent within 1 month prior to administration of study drug or planned receipt during the study period.
研究组 & 干预措施
Peginesatide
Experimental
干预措施: Peginesatide (Drug)
结局指标
主要结局
Maximum tolerated dose.
时间窗: End of Treatment.
次要结局
- Adverse events and serious adverse events.(At All Visits for every cycle.)
- Physical examination (including weight, vital signs, and oral temperature).(At All Visits for every cycle.)
- Pharmacokinetics of Peginesatide (PK Cohort Only).(At Each Visit for every cycle.)
- Proportion of subjects who have Hgb increases by more than 1 g/dL in a 2-week period.(At All Visits for every cycle.)
- Proportion of subjects who have 2 consecutive Hgb values of either an increase of ≥1 g/dL or a Hgb ≥11 g/dL in the absence of a red blood cell transfusion.(At All Visits for every cycle.)
- Proportion of subjects who have an increase in Hgb of ≥1 g/dL or a Hgb ≥11 g/dL in the absence of a red blood cell transfusion.(Days 22 and 43 for every cycle.)
- Change from Baseline in Hemoglobin.(At Each Visit for every cycle.)
- Proportion of subjects with 2 consecutive Hgb values increase of ≥1 g/dL or ≥11 g/dL during the Treatment phase absent of red blood cell transfusion within the prior 28 days and without excursion of Hgb values above 12 g/dL for ≥2 consecutive weeks.(Within the prior 28 days of every cycle for a minimum of 2 consecutive weeks.)
- Proportion of subjects who received at least 1 RBC transfusion.(From Day 29 to End of Treatment for every cycle.)
- Clinical Laboratory Tests and Electrocardiograms.(At All Visits for every cycle.)
- Electrocardiograms.(At Final Visit for every cycle.)
- Duration of maintaining Hgb values within the range of 10.5 g/dL and 12.0 g/dL.(At Each Visit for every cycle.)
- Signs and symptoms for thromboembolytic events.(At All Visits for every cycle.)
- Proportion of subjects who have incidence of Hgb values >12 g/dL.(At All Visits for every cycle.)
- Tumor progression.(Every 2 cycles of chemotherapy.)
研究者
相似试验
Unknown
1 期
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsSolid TumorsNCT03634982Revolution Medicines, Inc.133
招募中
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerAdvanced Prostate CancerMetastatic Prostate CancerNCT05800665Genentech, Inc.210
尚未招募
1 期
A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid TumorsAdvanced Solid TumorNCT05344742CSPC ZhongQi Pharmaceutical Technology Co., Ltd.116
进行中（未招募）
1 期
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT05835986Hoffmann-La Roche70
Unknown
1 期
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid TumorsMedulloblastomaAdenocarcinoma of Esophagogastric JunctionSmall Cell Lung CancerNeuroendocrine NeoplasmBasal Cell CarcinomaGlioblastomaNCT03734913Guangdong Zhongsheng Pharmaceutical Co., Ltd.65